Page last updated: 2024-12-07

xylidyl blue i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xylidyl blue I: RN from Chem Abstracts Index Guide 1984; RN not in Chemline 5/84 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135442960
SCHEMBL ID2861735
MeSH IDM0121485

Synonyms (22)

Synonym
xylidyl blue i
einecs 239-012-8
14936-97-1
1-azo-2-hydroxy-3-(2,4-dimethylcarboxyanilido)naphthalene-1'-(2-hydroxybenzene-5-sulfonic acid) sodium salt
2-[2-hydroxy-3-(2,4-xylylcarbamoyl)-1-naphthylazo]-1-phenol-4-sulfonic acid sodium salt
sodium 3-((3-(((2,4-dimethylphenyl)amino)carbonyl)-2-hydroxy-1-naphthyl)azo)-4-hydroxybenzenesulphonate
magonsulfonate
FT-0637162
SCHEMBL2861735
AKOS024285054
xylidyl blue i sodium salt
J-610035
mfcd00003890
xb-i; magonsulfonate
sodium (e)-3-((3-(2,4-dimethylphenylcarbamoyl)-2-hydroxynaphthalen-1-yl)diazenyl)-4-hydroxybenzenesulfonate
T70316
xylylazo violet i [spectrophotometric reagent for mg]
sodium3-(2-(3-((2,4-dimethylphenyl)carbamoyl)-2-oxonaphthalen-1(2h)-ylidene)hydrazineyl)-4-hydroxybenzenesulfonate
2321383-50-8
sodium 3-(2-(3-((2,4-dimethylphenyl)carbamoyl)-2-oxonaphthalen-1(2h)-ylidene)hydrazineyl)-4-hydroxybenzenesulfonate
sodium;3-[[3-[(2,4-dimethylphenyl)carbamoyl]-2-hydroxynaphthalen-1-yl]diazenyl]-4-hydroxybenzenesulfonate
SODIUM (E)-3-((3-((2,4-DIMETHYLPHENYL)CARBAMOYL)-2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL)-4-HYDROXYBENZENESULFONATE
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]